Growing cancer incidences, expansion of treatment into earlier-stage adjuvant settings, increasing demand for combination therapies, expanding applications, growing approvals, and increasing innovations are promoting the market growth.
Market at a Glance: Mapping the U.S. Immune Checkpoint Inhibitor Breakthrough
The immune checkpoint inhibitors are the cancer immunotherapy drugs that recognize and destroy cancer cells with enhanced T-cell activity and immune system response, by blocking inhibitory immune checkpoint pathways. They are used as cancer therapy, adjuvant therapy, neoadjuvant therapy, combination therapy, and precision immunotherapy. Moreover, their growing applications for the treatment of lung cancer, bladder cancer, neck cancer, kidney cancer, etc., are also driving their adoption rates.
Market Growth
The global immune checkpoint inhibitors market size was estimated at USD 58.72 billion in 2025 and is predicted to increase from USD 65.09 billion in 2026 to approximately USD 164.34 billion by 2035, expanding at a CAGR of 10.84% from 2026 to 2035.
Redefining Cancer Care: Future Opportunities Shaping the U.S. Market
- The rapid growth of multiple cancer types across the U.S. is increasing the demand and adoption of the immune checkpoint inhibitors.
- The growing adoption of early-stage treatment options is also increasing their use.
- Expanding precision medicine advancements are also driving the development of new immune checkpoint inhibitors.
- Rising discoveries of checkpoint targets are also propelling the development of next-generation therapies.
- Increasing innovations in combination therapies are also driving the immune checkpoint inhibitors advancements.
- Growing R&D activities supported by high healthcare investments are also creating new opportunities for their innovations.
The graph represents the estimated number of lung and bronchus cancer new cases and deaths in the U.S. for the year 2026. It indicates that there will be a rise in lung cancer burden, which will drive the demand for effective treatment options. This, in turn, will increase the adoption of immune checkpoint inhibitors to reduce the growing cancer burden across the U.S., which will ultimately promote the market growth.
Market Segmentation Overview
- By drug type, the PD-1 inhibitors segment accounted for the highest revenue share of 58% of the U.S. immune checkpoint inhibitors market in 2025 and is expected to witness the fastest growth with a CAGR of 11.20% during the forecast period, due to their high response rates and broader effectiveness. Their enhanced safety profiles and combination therapy success also increased their use. Growth in their approvals also increased their adoption.
- By indication type, the lung cancer segment held a major revenue share of 34% of the U.S. immune checkpoint inhibitors market in 2025, driven by growth in its incidence rates and high unmet needs. This increased the use of immune checkpoint inhibitors as a first-line therapy. Their significant survival benefits also increased their use in combination regimens and for the treatment of advanced cancers.
- By end user, the hospitals segment held the largest revenue share of 62% of the U.S. immune checkpoint inhibitors market in 2025, due to the presence of trained personnel supporting specialized drug administrations. High patient volume also increased the use of immune checkpoint inhibitors for the management and treatment of multiple cancers. The presence of reimbursement policies and combination therapies also attracted the patients.
- By distribution channel type, the hospital pharmacies segment contributed the biggest revenue share of 68% of the U.S. immune checkpoint inhibitors market in 2025, driven by oncology treatment integration and IV administration settings. Their specialized handling and prescription control also increased their acceptance rates. Patient monitoring and immediate access to care also increased their use.
- By therapy type, the combination therapy segment led the U.S. immune checkpoint inhibitors market with 54% share in 2025 and is expected to gain the highest share with a CAGR of 12.30% during the forecast period, due to their improved efficacy and response rates. Their faster responses and ability to overcome resistance also increased their adoption. Growth in their approval rates also promoted their use as a first-line therapy.
Regional Analysis
The U.S. immune checkpoint inhibitors market held 34% share in 2025 and is expected to show lucrative growth during the forecast period, due to growth in the cancer burden and health awareness. The presence of advanced healthcare infrastructure and favorable reimbursement policies also increased their use and accessibility. Well-established companies contributing to growth in the R&D activities and clinical trials also increased their advancements, which enhanced the market growth.
The U.S. Powerhouses: Top Immune Checkpoint Inhibitor Companies
Merck & Co. dominated the market with its Keytruda, where Bristol Myers Squibb was its closest contender, which offered Opdivo, Opdualag, and Yervoy. Roche (Genentech) also sustained its position by providing Tecentriq, where AstraZeneca also contributed to the market growth with its Imfinzi and Imjudo products.
Segments Covered in the Report
By Drug Type
- PD-1 Inhibitors
- Nivolumab
- Pembrolizumab
- Cemiplimab
- PD-L1 Inhibitors
- Atezolizumab
- Durvalumab
- Avelumab
- CTLA-4 Inhibitors
By Indication
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer (SCLC)
- Melanoma
- Renal Cell Carcinoma
- Hodgkin Lymphoma
- Head & Neck Cancer
- Bladder Cancer
- Others
- Gastric Cancer
- Liver Cancer
- Triple-negative Breast Cancer
By End User
- Hospitals
- Cancer Treatment Centers
- Research Institutes
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Therapy Type
- Monotherapy
- Combination Therapy
- With Chemotherapy
- With Targeted Therapy
- Dual Immunotherapy
